355 related articles for article (PubMed ID: 29500617)
21. The approval process for biosimilar erythropoiesis-stimulating agents.
Wish JB
Clin J Am Soc Nephrol; 2014 Sep; 9(9):1645-51. PubMed ID: 24970875
[TBL] [Abstract][Full Text] [Related]
22. Biosimilar medicines used for cancer therapy in Europe: a review.
Santos SB; Sousa Lobo JM; Silva AC
Drug Discov Today; 2019 Jan; 24(1):293-299. PubMed ID: 30244082
[TBL] [Abstract][Full Text] [Related]
23. Epoetin alfa-epbx: a new entrant into a crowded market. a historical review of the role of erythropoietin stimulating agents and the development of the first epoetin biosimilar in the United States.
Anand S; Al-Mondhiry J; Fischer K; Glaspy J
Expert Rev Clin Pharmacol; 2021 Jan; 14(1):1-8. PubMed ID: 33307871
[No Abstract] [Full Text] [Related]
24. Biosimilars: A Multidisciplinary Perspective.
Khraishi M; Stead D; Lukas M; Scotte F; Schmid H
Clin Ther; 2016 May; 38(5):1238-49. PubMed ID: 26988243
[TBL] [Abstract][Full Text] [Related]
25. Ten years of biosimilars in Europe: development and evolution of the regulatory pathways.
Schiestl M; Zabransky M; Sörgel F
Drug Des Devel Ther; 2017; 11():1509-1515. PubMed ID: 28553082
[TBL] [Abstract][Full Text] [Related]
26. Results from a safety cohort of patients with renal anemia receiving the biosimilar epoetinzeta: The PASCO I study.
Dellanna F; Fluck RJ; Lonnemann G; Wild CA; Iwanowitsch A; Meissner R; Audhya P
Clin Nephrol; 2015 Nov; 84(5):280-8. PubMed ID: 26396097
[TBL] [Abstract][Full Text] [Related]
27. The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions.
Bennett CL; Nagai S; Bennett AC; Hoque S; Nabhan C; Schoen MW; Hrushesky WJ; Luminari S; Ray P; Yarnold PR; Witherspoon B; Riente J; Bobolts L; Brusk J; Tombleson R; Knopf K; Fishman M; Yang YT; Carson KR; Djulbegovic B; Restaino J; Armitage JO; Sartor OA
Oncologist; 2021 Aug; 26(8):e1418-e1426. PubMed ID: 33586299
[TBL] [Abstract][Full Text] [Related]
28. Biosimilar safety considerations in clinical practice.
Choy E; Jacobs IA
Semin Oncol; 2014 Feb; 41 Suppl 1():S3-14. PubMed ID: 24560025
[TBL] [Abstract][Full Text] [Related]
29. Future Evolution of Biosimilar Development by Application of Current Science and Available Evidence: The Developer's Perspective.
Cohen HP; Turner M; McCabe D; Woollett GR
BioDrugs; 2023 Sep; 37(5):583-593. PubMed ID: 37542600
[TBL] [Abstract][Full Text] [Related]
30. Introduction of Biosimilar Therapeutics Into Nephrology Practice in the United States: Report of a Scientific Workshop Sponsored by the National Kidney Foundation.
Wish JB; Charytan C; Chertow GM; Kalantar-Zadeh K; Kliger AS; Rubin RJ; Yee J; Fishbane S
Am J Kidney Dis; 2016 Dec; 68(6):843-852. PubMed ID: 27599628
[TBL] [Abstract][Full Text] [Related]
31. Biosimilar medical products - licensing, pharmacovigilance and interchangeability.
Grozdanova A; Netkovska KA; Sterjev Z; Naumovska Z; Zarevski R; Dimovski A; Suturkova L
Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2016; 37(1):27-36. PubMed ID: 27442414
[TBL] [Abstract][Full Text] [Related]
32. Review article: biosimilars are the next generation of drugs for liver and gastrointestinal diseases.
Rinaudo-Gaujous M; Paul S; Tedesco ED; Genin C; Roblin X; Peyrin-Biroulet L
Aliment Pharmacol Ther; 2013 Oct; 38(8):914-24. PubMed ID: 24001128
[TBL] [Abstract][Full Text] [Related]
33. Biosimilars in ulcerative colitis: When and for who?
Ilias A; Gonczi L; Kurti Z; Lakatos PL
Best Pract Res Clin Gastroenterol; 2018; 32-33():35-42. PubMed ID: 30060937
[TBL] [Abstract][Full Text] [Related]
34. Clinical safety of biosimilar recombinant human erythropoietins.
Abraham I; MacDonald K
Expert Opin Drug Saf; 2012 Sep; 11(5):819-40. PubMed ID: 22880621
[TBL] [Abstract][Full Text] [Related]
35. Biosimilar safety factors in clinical practice.
Reinisch W; Smolen J
Semin Arthritis Rheum; 2015 Jun; 44(6 Suppl):S9-15. PubMed ID: 26058551
[TBL] [Abstract][Full Text] [Related]
36. Biosimilars in the therapy of inflammatory bowel diseases.
Hlavaty T; Letkovsky J
Eur J Gastroenterol Hepatol; 2014 Jun; 26(6):581-7. PubMed ID: 24722561
[TBL] [Abstract][Full Text] [Related]
37. Biosimilars: impact of biologic product life cycle and European experience on the regulatory trajectory in the United States.
Ahmed I; Kaspar B; Sharma U
Clin Ther; 2012 Feb; 34(2):400-19. PubMed ID: 22244050
[TBL] [Abstract][Full Text] [Related]
38. [Biosimilars--opportunity or threat?].
Swierkot J
Wiad Lek; 2013; 66(2 Pt 2):200-5. PubMed ID: 25775818
[TBL] [Abstract][Full Text] [Related]
39. Developing clinical trials for biosimilars.
Bui LA; Taylor C
Semin Oncol; 2014 Feb; 41 Suppl 1():S15-25. PubMed ID: 24560024
[TBL] [Abstract][Full Text] [Related]
40. Evolution of the EU Biosimilar Framework: Past and Future.
Wolff-Holz E; Tiitso K; Vleminckx C; Weise M
BioDrugs; 2019 Dec; 33(6):621-634. PubMed ID: 31541400
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]